Skip to main content
Top
Published in: Annals of Surgical Oncology 10/2013

01-10-2013 | Breast Oncology

Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort

Authors: Rachel Greenup, MD, MPH, Adam Buchanan, MPH, MS, Wendy Lorizio, MD, MPH, Keelia Rhoads, PhD, Salina Chan, MD, Tracey Leedom, MS, Robin King, MS, Jane McLennan, MD, PhD, Beth Crawford, MS, P. Kelly Marcom, MD, E. Shelley Hwang, MD, MPH

Published in: Annals of Surgical Oncology | Issue 10/2013

Login to get access

Abstract

Background

Revised NCCN guidelines recommend that women ≤60 years with triple-negative breast cancer (TNBC) be referred for consideration of genetic counseling. Small, homogeneous samples have limited evaluation of BRCA mutation prevalence among different ethnicities affected by TNBC subtype. We sought to determine whether the prevalence of BRCA mutations within a TNBC cohort differs by demographic factors.

Methods

We performed a retrospective review of patients with TNBC referred for genetic counseling at two academic Hereditary Cancer Clinics between 2000 and 2012. Demographic data were collected, including age at diagnosis and race/ethnicity. Race was categorized as African American (AA), Ashkenazi Jewish (AJ), Asian, Caucasian, Hispanic, or other. Primary outcome was BRCA mutation status, analyzed by race/ethnicity and age at diagnosis.

Results

A total of 469 patients with TNBC who underwent testing for BRCA genetic mutations were identified, of which 450 patients had evaluable BRCA testing results; 139 (30.8 %) had confirmed BRCA1 (n = 106) or BRCA2 (n = 32) mutations. BRCA mutation prevalence differed by ethnicity and race: AA (20.4 %), AJ (50 %), Asian (28.5 %), Caucasian (33.3 %), and Hispanic (20 %). The prevalence of genetic mutations also differed by age at diagnosis: <40 years (43.8 %), 40–49 years (27.4 %), 50–59 years (25.3 %), 60–69 years (12.5 %), and >70 years (16.6 %).

Conclusions

The prevalence of genetic mutations among women with TNBC referred for genetic counseling is high and differs significantly by ethnicity/race and age. This data helps to refine mutation risk estimates among women with TNBC, allowing for more personalized genetic counseling potentially aiding in improved patient decision-making.
Literature
1.
go back to reference Daly MB, Axilbund JE, Buys S, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Cancer Netw. 2010;8:562–94. Daly MB, Axilbund JE, Buys S, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Cancer Netw. 2010;8:562–94.
2.
go back to reference Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;9:86.PubMedCrossRef Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;9:86.PubMedCrossRef
3.
go back to reference Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple-negative breast cancer. Clin Cancer Res. 2011;17(5):1082–9.PubMedCrossRef Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple-negative breast cancer. Clin Cancer Res. 2011;17(5):1082–9.PubMedCrossRef
4.
go back to reference Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118:2787–95.PubMedCrossRef Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118:2787–95.PubMedCrossRef
5.
go back to reference Robertson L, Hanson H, Seal S, et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer. 2012;106:1234–8.PubMedCrossRef Robertson L, Hanson H, Seal S, et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer. 2012;106:1234–8.PubMedCrossRef
6.
go back to reference National Comprehensive Cancer Network, NCCN Guidelines Version 2.2013. Hereditary Breast and/or Ovarian Cancer Syndrome. NCCN.org. National Comprehensive Cancer Network, NCCN Guidelines Version 2.2013. Hereditary Breast and/or Ovarian Cancer Syndrome. NCCN.org.
7.
go back to reference Comen E, Davids M, Kirchoff T, et al. Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi women. Breast Cancer Res Treat. 2011;129:185–90.PubMedCrossRef Comen E, Davids M, Kirchoff T, et al. Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi women. Breast Cancer Res Treat. 2011;129:185–90.PubMedCrossRef
8.
go back to reference Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst. 1999;91:1241–7.PubMedCrossRef Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst. 1999;91:1241–7.PubMedCrossRef
9.
go back to reference Armstrong K, Calzone K, Stopfer J, et al. Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomark Prev. 2000;9:1251. Armstrong K, Calzone K, Stopfer J, et al. Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomark Prev. 2000;9:1251.
10.
go back to reference Hall MJ, Reid JE, Burbige LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115:2222–33.PubMedCrossRef Hall MJ, Reid JE, Burbige LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115:2222–33.PubMedCrossRef
11.
go back to reference Berry DA, Iversen ES, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20:2701–12.PubMedCrossRef Berry DA, Iversen ES, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20:2701–12.PubMedCrossRef
12.
go back to reference Tai YC, Chen S, Parmigiani C, et al. Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction. Breast Cancer Res. 2008;10(2):401.PubMedCrossRef Tai YC, Chen S, Parmigiani C, et al. Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction. Breast Cancer Res. 2008;10(2):401.PubMedCrossRef
13.
go back to reference Kwon JS, Gutierrez-Barrera AM, Young D, et al. Expanding the criteria for BRCA mutation testing breast cancer survivors. J Clin Oncol. 2010;28:4214–20.PubMedCrossRef Kwon JS, Gutierrez-Barrera AM, Young D, et al. Expanding the criteria for BRCA mutation testing breast cancer survivors. J Clin Oncol. 2010;28:4214–20.PubMedCrossRef
14.
go back to reference Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28:893–901.PubMedCrossRef Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28:893–901.PubMedCrossRef
15.
go back to reference American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397–406.CrossRef American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397–406.CrossRef
Metadata
Title
Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort
Authors
Rachel Greenup, MD, MPH
Adam Buchanan, MPH, MS
Wendy Lorizio, MD, MPH
Keelia Rhoads, PhD
Salina Chan, MD
Tracey Leedom, MS
Robin King, MS
Jane McLennan, MD, PhD
Beth Crawford, MS
P. Kelly Marcom, MD
E. Shelley Hwang, MD, MPH
Publication date
01-10-2013
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 10/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-3205-1

Other articles of this Issue 10/2013

Annals of Surgical Oncology 10/2013 Go to the issue